Brexit: IP one of the ‘least affected’ areas

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Brexit: IP one of the ‘least affected’ areas

AIPPI-2019-Brexit-panel-thumb

Speakers from the UKIPO and Novartis discussed Brexit at the AIPPI World Congress in London, as political protesters gathered outside the Supreme Court just round the corner

AIPPI-2019-Brexit-panel

The panel on Brexit yesterday could not have been more timely: as demonstrators gathered in front of the nearby UK Supreme Court to protest against the temporary suspension of Parliament, the speakers in the QEII Centre kicked off a discussion on how Brexit will affect IP.

Adam Williams, director of international policy at the UKIPO, began the session by telling audience members that his office has been working diligently to ensure a smooth transition for Brexit.

Williams went on to explain that Parliament has only granted his office permission to fix any gaps in legislation and not to tinker with policy changes.

The panellists said patents will be the area of IP least affected by Brexit because of pre-existing international harmonisation.

“Our real focus is trademarks and designs,” Williams said. “After leaving the EU, coverage of these rights will no longer extend to the UK. In the event of no-deal we are committed to giving owners rights similar to the EU rights they had before. Similar arrangements are being made as part of the withdrawal agreement.”

One area of concern for patent owners in the event of a no-deal Brexit is supplementary protection certificates (SPCs).

Williams said: “We recognise that while not many are issued, we know how valuable they are to pharmaceutical companies. In the event of a no-deal we will maintain a functioning SPC regime along the lines of the current system with the same rules and same timing periods and rights for those certificates.”

Ewan Nettleton, senior patent counsel for oncology at Novartis in Switzerland, said he was very pleased with all the provisions made by the UKIPO in preparation for Brexit. As SPCs are of particular importance to his industry, he emphasised that many of the same rights will be extended after Brexit.

“For us at Novartis, thanks to Adam’s diligent work, I am here to say we feel less uncomfortable. It appears that IP is one of the least affected areas by Brexit,” he said.

The Unified Patent Court (UPC) was discussed as a potential Brexit-related concern. With the UPC’s fate lingering in Germany’s Constitutional Court, audience members speculated on how the timing of the court’s decision might be affected by Brexit.

Responding to an audience member’s concern, Williams said any conversation about whether or not the UK – which has ratified the UPC Agreement – would be part of an operational UPC would depend on when Germany issues a decision. 

“In a perfect world you will like us to have the discussion while we are in the EU; logically that is a more pleasant environment. If we exit in October … the conversation is in a more different atmosphere. We are sure of the benefits of the UK to be part of the UPC. My experience says if there is a political will you will find a legal solution.”

Nettleton added that from an industry perspective the UPC would be much stronger with UK involvement.

“It was a surprise to me that I heard the UK would still want to participate in the UPC after Brexit. But then again, after Brexit, nothing can surprise you,” he said.

The Congress finishes today.

Image credit: Simon Callaghan Photography

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article